 This is a multicentre study in which women were planned to receive either the Human Papillomavirus Vaccine HPV vaccine or control. Under Protocol Amendment 3, study participation will last approximately 48 months and involves a total of eleven scheduled visits. Under Protocol Amendment 4, study participation will last up to 84 months and involves a maximum of seventeen scheduled visits. 